Results 201 to 210 of about 56,167 (240)

Management of Latent Tuberculosis Infection

JAMA, 2023
This JAMA Insights Clinical Update examines treatment recommendations and therapy options among adults with latent tuberculosis infection.
Steven, Kim, Rebecca, Thal, Daria, Szkwarko   +2 more
openaire   +2 more sources

Treatment of Latent Tuberculosis Infection

Annals of Internal Medicine, 2015
possible comparisons, 42 (40%) were compared directly. Compared with placebo, isoniazid for 6 months (odds ratio [OR], 0.64 [95% credible interval {CrI}, 0.48 to 0.83]) or 12 months or longer (OR, 0.52 [CrI, 0.41 to 0.66]), rifampicin for 3 to 4 months (OR, 0.41 [CrI, 0.18 to 0.86]), rifapentine-isoniazid (OR, 0.61 [CrI, 0.29 to 1.22]), and rifampicin ...
Dominik, Zenner, Helen R, Stagg, Ross J, Harris, Ibrahim, Abubakar   +3 more
openaire   +4 more sources

Latent Tuberculosis Infection

New England Journal of Medicine, 2021
Maunank, Shah, Susan E, Dorman
openaire   +2 more sources

Latent Tuberculosis Infection

New England Journal of Medicine, 2022
openaire   +2 more sources

Treatment of latent tuberculosis infection

Seminars in Respiratory Infections, 2003
Treatment of latent tuberculosis infection (LTBI) is considered an essential component of TB control programs in several industrialized countries and is being used in selected situations in developing countries. In 2000, the American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) published new recommendations on the ...
openaire   +2 more sources

Latent tuberculosis infection

Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti, 2012
Latent tuberculosis infection (LTBI) is a subclinical infection with Mycobacterium (M.) tuberculosis. Children and immunosuppressed individuals due to pathologic conditions or therapeutic procedures are at a high risk of reactivation of LTBI to active disease compared to general population and require timely identification.
openaire   +2 more sources

Anti-tuberculosis treatment strategies and drug development: challenges and priorities

Nature Reviews Microbiology, 2022
Véronique A Dartois, Eric J Rubin
exaly  

Immune evasion and provocation by Mycobacterium tuberculosis

Nature Reviews Microbiology, 2022
Pallavi Chandra, Steven J Grigsby, Jennifer A Philips   +2 more
exaly  

Enhancing global access to cancer medicines

Ca-A Cancer Journal for Clinicians, 2020
Javier Cortes, Giuseppe Curigliano, Nagi S El Saghir   +2 more
exaly  

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

Nature Reviews Microbiology, 2009
Clifton E Barry Iii, Helena I Boshoff, Thomas Dick   +2 more
exaly